medigraphic.com
Colegio de Medicina Interna de México.

2012, Number 3

<< Back Next >>

Med Int Mex 2012; 28 (3)

Pentoxifylline versus steroid in short-term survival in severe acute alcoholic hepatitis

Garrido GJR, Sánchez HG, Melchor LA, Elizalde BCI, Sánchez VL

Language: Spanish
References: 34
Page: 227-233
PDF size: 388.25 Kb.


ABSTRACT

Background: Alcoholic hepatitis (AH) severe is a cholestatic liver disease, with high mortality rate. The main factor involved in the genesis is the Tumor Necrosis Factor-alpha (TNF-α). There are no conclusive studies that support what is the best treatment using either PTX or corticosteroids. Objective: To compare the short-term survival in AH severe, using PTX or corticosteroids.
Material and methods: Sixty patients with AH severe (Maddrey score ›32) received PTX (n = 30) or prednisone [PDN] (n = 30) for 28 days, in a randomized controlled clinical study. The primary endpoint of the study was the effect of PTX in the short-term survival compared with corticosteroid. Secondary point was the appearance and development of hepatorenal syndrome with the use of PTX.
Results: Fourteen patients in the PTX group and 18 patients in the PDN group died (46.66 vs. 59.99%, p = 0.30). Thirteen patients in the PDN group developed SHR, compared with 6 patients in the PTX group (RR 0.53; IC 95%: 0.04-0.35, p = 0.05,).
Conclusions: No difference was found in both treatment groups in the short-term survival in the severe AH. The PTX decreased the risk of developing SHR. There were not other variables related to survival by treatment group.


REFERENCES

  1. Cohen SM. Review article: The diagnosis and management of alcoholic hepatitis. Aliment PharmacolTher. 2009;30(1):3-13.

  2. Yu Ch, Xu CF, et al. Early mortality of alcoholic hepatitis: a review of data from placebo-controleed clinical trials. World-Gastroenterol. 2010;16(19):2435-2439.

  3. Higuera de la Tijera, Pérez Hernández. Cantidad de alcohol, hemorragia de tubo digestivo alto, insuficiencia renal aguda y encefalopatía hepática como factores de riesgo implicados en el incremento de la mortalidad en pacientes con hepatitis por alcohol. Rev Gastroenterol Mex 2009;74(4):306-313.

  4. Rodríguez M. Martínez G y col. Tratamiento de la hepatitis tóxica grave por alcohol. Estudio comparativo entre dos medidas terapéuticas: sulfoadenosil-L-metionina (SAMe) vs SAMe más metilprednisolona. Med Int Mex 2004:20:18-23.

  5. Lucey MR, Mathurin P, et al. Medical Preogress: Alcoholic Hepatitis. N Engl J Med 2009;360:2758-2769.

  6. O´Shea R, Srinivasan D, at al. ACG Practice Guidelines. Alcoholic Liver Disease. Am J Gastroenterol 2010;105:14-32.

  7. Higuera de la Tijera, Pérez Hernández y col. Hepatitis Alcohólica. Rev Med Hosp Gen Mex 2009;72(4):215-221.

  8. Gramenzi F, Caputo F, et al. Review article: alcoholic liver disease–pathophysiological aspects and risk factors. Aliment Pharmacol Ther 2006;24;1151-1161.

  9. Tan HH, Virmani S, et al. Controversies in the management of alcoholic liver disease. Mt Sinai J Med 2009:76(5):484-498.

  10. Amini M, Runyon B, et al. Alcoholic hepatitis 2010: a clinican´s guide to diagnosis and theraphy. World J Gastroenterol 2010;16(39):4905-4912.

  11. Altamirano Gómez, Zapata Irisson y col. Utilidad clínica y predicción de supervivencia intrahospitalaria de 3 escalas pronósticas en hepatitis alcohólica. Rev Gastroenterol Mex 2009;74(1):18-25.

  12. Forrest H, Evans J. et al. Anlysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005;54:1174-1179.

  13. Lucey R. Management of Alcholic Liver Disease. Clin Liver Dis 2009; 13: 267-275

  14. O´Shea R, McCullouh J. Steroids or cocktails for alcoholic hepatitis. Journal of Hepatology 2006;44:633-636.

  15. Akriviadis E, Botla R, et al. Pentoxifylline Improves Short-term Survival in Severe Acute Alcoholic Hepatitis: A Double-Blind, Placebo-Controlled Trial. Gastroenterology 2000;119:1637-1648.

  16. Cárdenas A. Gines P. HepatorrenalSyndrome. Clini Liver Dis 2006;10:371-385.

  17. Hardman G, Limbird L. Goodman and Gilman.Las bases farmacológicas de la terapéutica. Vol. II. Decima Edición 2003. McGraw-Hill. pp. 1601.

  18. De BK, Gangopadhayay S. et al. Pentoxifylline versus Prednisolone for severe alcohoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009;15(3):1613-1619.

  19. Mathurin P., O´Grady J, et al. Corticoesteroids improve 28-day survival in patients with severe alcohol hepatitis: Individual data analysis of the last 5 randomized controlled trials.

  20. Rambaldi A. Saconato H. Systematic review: glucorticosteroids for alcoholic hepatitis-a Cochrane Hepato.Biliary Group systematic review with meta-analyses and trials sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 2008;27(12):116-178.

  21. Louvet A, Diaz E, et al. Early switch to pentoxifilline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. Journal of Hepatology 2008;48:465-470.

  22. Lebrec D, Thabut D. Pentoxifylline does not decrease shortterm mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterolgy 2010;138: 1755-1762.

  23. Louvet A., Diaz E. et al. Early switch to pentoxifilline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. Journal of Hepatology 2008; 48: 465-470.

  24. Whitfield K, Rambaldi A. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009;(4):CD007339.

  25. Louvet A, Wartel F. Infection en patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009;137(2):541-548.

  26. Barve A, Khan R. Treatment of alcoholic liver disease. Annals of Hepatology 2008;7(1):5-15.

  27. Arentes V, Piña M. Unusual infections complicating the use of steroids with severe alcoholic hepatitis: Report of two cases. Gastroenterology 1995;9(2):81-83.

  28. Stewart S, Prince M. A randomized trial of antioxidant therapy alone or with corcosteriods in acute alcoholic hepatitis. Journal of Hepatology 2007;47:277-283.

  29. Jackson P. Gleeson D. Alcoholic Liver Disease. Anaesth Crit Care and Pain 2010;10(3):66-71.

  30. Moreno C. Enteral nutrition with or without N-acetylcisteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol 2010;53(6):1117-1122.

  31. Sharma P, Kumar A. Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: An open label trial. Journal of Hepatology 2008:50:548-591.

  32. Boetticher NC, Peine CJ. A randomized, double-blinded, placebo-controllated multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008;135(6):1953-1960.

  33. Morris JM, Dickson S. Granulocytapheresis in the treatment of severe hepatitis; a case series. Eur J Gastroenterol 2010;22(4):457-460.

  34. Varma V. Liver transplantation for alcoholic liver disease. Worl J Gastroenterol 2010;16(35):4377-4393.




2020     |     www.medigraphic.com